SCHEMBL14734758

SCHEMBL14734758

CCOc1c(OC)ccc(-c2ccc3c(c2)CNC3=O)c1OCC(=O)OCC1CC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLQ O75417 2/20 0.39
GSK3B P49841 2/20 0.38
PRF1 P14222 1/20 0.35
MAPKAPK2 P49137 1/20 0.35
PDE3B Q13370 1/20 0.35
PDE3A Q14432 1/20 0.35
PRKACA P17612 1/20 0.35
PRKACG P22612 1/20 0.35
PRKACB P22694 1/20 0.35
PDE4B Q07343 1/20 0.35
DAPK3 O43293 1/20 0.34
NTRK1 P04629 1/20 0.34
PIM1 P11309 1/20 0.34
FLT3 P36888 1/20 0.34
ROCK1 Q13464 1/20 0.34
CLK4 Q9HAZ1 1/20 0.34
PRKCI P41743 1/20 0.34
PADI4 Q9UM07 3/20 0.33
TDP2 O95551 1/20 0.33
ADORA2A P29274 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2591661 0.97 GSK3B (0.37) POLQGSK3BPRF1MAPKAPK2PDE3B
SCHEMBL2592264 0.94 POLQ (0.41) POLQGSK3BPRF1MAPKAPK2PRKACA
SCHEMBL2588425 0.91 POLQ (0.40) POLQGSK3BPRF1MAPKAPK2DAPK3
SCHEMBL2588354 0.90 GSK3B (0.39) POLQGSK3BPRF1MAPKAPK2PRKACA
SCHEMBL14734708 0.88 POLQ (0.37) POLQGSK3BPRF1MAPKAPK2DAPK3
SCHEMBL2592541 0.88 POLQ (0.41) POLQGSK3BPRF1MAPKAPK2DAPK3
SCHEMBL2591044 0.87 ALDH1A1 (0.39) POLQGSK3BPRF1MAPKAPK2DAPK3
SCHEMBL14737996 0.87 MAPT (0.40) POLQGSK3BPRF1MAPKAPK2PDE4B
SCHEMBL2588921 0.87 POLQ (0.36) POLQGSK3BPRF1MAPKAPK2PDE4B
SCHEMBL2593800 0.87 GSK3B (0.39) POLQGSK3BPRF1MAPKAPK2PDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2563770-B1 BIARYL PHOSPHODIESTERASE INHIBITORS LEO PHARMA AS (DK) 2016-03-23 EP disclosed
US-9051290-B2 Biaryl phosphodiesterase inhibitors LEO PHARMA A/S (DK) 2015-06-09 US disclosed
US-9051290-B2 Biaryl phosphodiesterase inhibitors LEO PHARMA A/S (DK) 2015-06-09 US disclosed
US-9051290-B2 Biaryl phosphodiesterase inhibitors LEO PHARMA A/S (DK) 2015-06-09 US disclosed
US-20130059853-A1 BIARYL PHOSPHODIESTERASE INHIBITORS LEO PHARMA A/S (DK) 2013-03-07 US disclosed
US-20130059853-A1 BIARYL PHOSPHODIESTERASE INHIBITORS LEO PHARMA A/S (DK) 2013-03-07 US disclosed
US-20130059853-A1 BIARYL PHOSPHODIESTERASE INHIBITORS LEO PHARMA A/S (DK) 2013-03-07 US disclosed
EP-2563770-A1 BIARYL PHOSPHODIESTERASE INHIBITORS Leo Pharma A/S (DK) 2013-03-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130059853-A1 BIARYL PHOSPHODIESTERASE INHIBITORS PDE3B, PDE3A, PDE4A POLQ 1717/4885GSK3B 350/4885PRF1 3550/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.